From medicine to business and wellness
NYS Medicaid Fee-for-Service Policy Guidance for SPRAVATO® (Esketamine) Nasal Spray
The New York State (NYS) Medicaid Drug Utilization Review (DUR) Board recommended some criteria for Spravato® nasal spray under Pharmacy and Medical Benefit. This came into effect on August 11, 2022, which is mentioned hereafter:
Subscribe to get the latest posts sent to your email.
Effective September 15, 2021, EmblemHealth has instituted a Medical Policy for Allergy Testing. According to New York State Medicaid Guidelines,…
A landmark federal rule finally forces American healthcare to abandon its paper-and-fax past — but the real story is what…
Starting January 1, 2023, Applied Behavior Analysis services for Medicaid Managed Care enrollees will be covered by New York State…